Brigitte C. Widemann

Brigitte C. Widemann

Auto-generated profile, based on publicly available information

Brigitte C. Widemann

Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2004 in Cancer
Verified
Journal Article
Closed access
PDF file
BWBrigitte C. Widemann
Brigitte C. Widemann
FBFrank M. Balis
Frank M. Balis
BKBeate Kempf‐Bielack
Beate Kempf‐Bielack
SBStefan Bielack
Stefan Bielack
CPCharles B. Pratt
Charles B. Pratt
PAPeter C. Adamson
Peter C. Adamson

1 September 2000 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
BWBrigitte C. Widemann
Brigitte C. Widemann
ESEdward Sung
Edward Sung
LALawrence Anderson
Lawrence Anderson
WSWanda L. Salzer
Wanda L. Salzer
FBFrank M. Balis
Frank M. Balis
PAPeter C. Adamson
Peter C. Adamson

19 October 2004 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
BWBrigitte C. Widemann
Brigitte C. Widemann
FBFrank M. Balis
Frank M. Balis
ASAiman Shalabi
Aiman Shalabi
MBMatthew Boron
Matthew Boron
MOMichelle O'Brien
Michelle O'Brien
PAPeter C. Adamson
Peter C. Adamson
The bacterial enzyme carboxypeptidase G 2 (CPDG 2 ) rapidly hydrolyzes methotrexate to inactive metabolites. We administered recombinant CPDG 2 (2000 U) intrathecally to seven cancer patients 3 to 9 hours after they had received an accidental overdose of intrathecal methotrexate (median dose = 364 mg; range = 155–600 mg). Four of the seven patients had cerebrospinal fluid (CSF) exchange to remove methotrexate before CPDG 2 administration. Immediate symptoms of the methotrexate overdoses included seizures (n = 5), coma (n = 2), and cardiopulmonary compromise (n = 2). Before CPDG 2 administration, the median concentrations of methotrexate in CSF were 264 μ M (range = 97–510 μ M ) among patients who had CSF exchange and 8050 μ M (range = 2439–16 500 μ M ) among patients who did not. After intrathecal CPDG 2 administration, methotrexate concentrations in CSF declined by more than 98%. All patients recovered completely from the intrathecal methotrexate overdose except for two patients who had memory impairments. Antibodies to CPDG 2 were not detected in plasma after treatment with intrathecal CPDG 2 . Intrathecal CPDG 2 is well tolerated, rapidly decreases CSF methotrexate concentrations, and appears to be efficacious for treating accidental intrathecal methotrexate overdoses.

1 March 2024 in Journal of Neuro-Oncology
Verified
Journal Article
Open access
PDF file
JRJames L. Rogers
James L. Rogers
TWThomas Wall
Thomas Wall
AAAlvina A. Acquaye-Mallory
Alvina A. Acquaye-Mallory
LBLisa Boris
Lisa Boris
YKYeonju Kim
Yeonju Kim
MPMarta Penas-Prado
Marta Penas-Prado
Purpose: Multidisciplinary tumor boards (MTBs) integrate clinical, molecular, and radiological information and facilitate coordination of neuro-oncology care. During the COVID-19 pandemic, our MTB transitioned to a virtual and multi-institutional format. We hypothesized that this expansion would allow expert review of challenging neuro-oncology cases and contribute to the care of patients with limited access to specialized centers. Methods: We retrospectively reviewed records from virtual MTBs held between 04/2020–03/2021. Data collected included measures of potential clinical impact, including referrals to observational or therapeutic studies, referrals for specialized neuropathology analysis, and whether molecular findings led to a change in diagnosis and/or guided management suggestions. Results: During 25 meetings, 32 presenters discussed 44 cases. Approximately half (n = 20; 48%) involved a rare central nervous system (CNS) tumor. In 21% (n = 9) the diagnosis was changed or refined based on molecular profiling obtained at the NIH and in 36% (n = 15) molecular findings guided management. Clinical trial suggestions were offered to 31% (n = 13), enrollment in the observational NCI Natural History Study to 21% (n = 9), neuropathology review and molecular testing at the NIH to 17% (n = 7), and all received management suggestions. Conclusion: Virtual multi-institutional MTBs enable remote expert review of CNS tumors. We propose them as a strategy to facilitate expert opinions from specialized centers, especially for rare CNS tumors, helping mitigate geographic barriers to patient care and serving as a pre-screening tool for studies. Advanced molecular testing is key to obtaining a precise diagnosis, discovering potentially actionable targets, and guiding management.

20 December 2020 in medRxiv
Verified
Preprint
Open access
PDF file
KWKarin S Walsh
Karin S Walsh
Wolters PamelaWolters Pamela
Wolters Pamela
BWBrigitte C. Widemann
Brigitte C. Widemann
ACAllison A. del Castillo
Allison A. del Castillo
MSMaegan D. Sady
Maegan D. Sady
RPRoger J. Packer
Roger J. Packer
Objective: NF1-associated cognitive impairments carry significant life-long morbidity. The lack of targeted biologic treatments remains a significant unmet need. We examine changes in cognition in patients with NF1 in the first 48 weeks of MEK inhibitor (MEKi) treatment. Methods: 59 NF1 patients ages 5-27 on a MEKi clinical trial treating plexiform neurofibroma underwent pre-treatment and follow-up cognitive assessments over 48-weeks of treatment. Performance tasks (Cogstate) and observer-reported functioning (BRIEF) were primary outcomes. Group-level (paired t -tests) and individual-level analyses (reliable change index; RCI) were used. Results: Analysis showed statistically significant improvements on BRIEF compared to baseline (24-week BRI: t (58) =3.03, p =.004, d =0.24; 48-week MCI: t (39) =2.70, p =.01, d =0.27). RCI indicated more patients had clinically significant improvement at 48-weeks than expected by chance ( Chi Square =11.95, p =.001, OR=6.3). Group-level analyses indicated stable performance on Cogstate ( p >.05). RCI statistics showed high proportions of improved working memory (24-weeks Chi Square =8.36, p =.004, OR=4.6 and 48-weeks Chi Square =9.34, p =.004, OR=5.3) but not visual learning/memory. Patients with baseline impairments on BRIEF were more likely to show significant improvement than non-impaired patients (24-weeks 46% v. 8%; Chi Square =9.54, p =.008, OR=9.22; 48-weeks 63% v. 16%; Chi Square =7.50, p =.02, OR=9.0). Interpretation: Our data shows no evidence of neurotoxicity in 48-weeks of treatment with a MEKi and a potential clinical signal supporting future research of MEKi as a cognitive intervention.